Related references
Note: Only part of the references are listed.Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry
G. Carretero et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)
Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Systemic psoriasis therapy shows high between-country variation: a sign of unwarranted variation? Cross-sectional analysis of baseline data from the PSONET registries
I. Garcia-Doval et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
German S3-guidelines on the treatment of psoriasis vulgaris (short version)
A. Nast et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2012)
Challenges for Synthesising Data in a Network of Registries for Systemic Psoriasis Therapies
A. D. Ormerod et al.
DERMATOLOGY (2012)
Co-morbidity and Age-related Prevalence of Psoriasis: Analysis of Health Insurance Data in Germany
Matthias Augustin et al.
ACTA DERMATO-VENEREOLOGICA (2010)
Epidemiology and comorbidity of psoriasis in children
M. Augustin et al.
BRITISH JOURNAL OF DERMATOLOGY (2010)
Memorandum Registry for Health Services Research
D. Mueller et al.
GESUNDHEITSWESEN (2010)
European S3-Guidelines on the systemic treatment of psoriasis vulgaris
D. Pathirana et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2009)
Psoriasis therapy in real life: The need for registries
Marcus Schmitt-Egenolf
DERMATOLOGY (2006)
The national database of the German Collaborative Arthritis Centres: I. Structure, aims, and patients
A Zink et al.
ANNALS OF THE RHEUMATIC DISEASES (2001)
Share Paper
